NY-IFF
IFF (NYSE:IFF) today released its 2022 Do More Good Report, which highlights performance and progress against goals set forth in the Do More Good Plan, the Company’s environmental, social, governance, plus sustainable solutions (or ESG+) strategy and roadmap that activates its purpose of applying science and creativity for a better world.
The Do More Good Report: IFF’s 2022 ESG+ Progress, describes the first full year of performance and progress as One IFF following the 2021 merger with DuPont’s Nutrition & Biosciences division. IFF will hold a live webcast to discuss the Company’s Do More Good Plan and goals, 2022 ESG+ results, and 2023 sustainability outlook on May 23, 2023, at 9:00 a.m. ET.
“When we launched our Do What Matters Most strategy in 2022, we committed to embedding ESG+ in all we do,” said Frank Clyburn, IFF CEO. “Our 2022 Do More Good Report illustrates the steps we’re taking to deliver on our commitments to address sustainable development imperatives. Our world-class R&D program and commitment to innovation fuels a pipeline of exciting sustainable solutions that are helping our customers reach their ESG goals and, in turn, responding to heightened consumer expectations on sustainability.”
The 2022 Do More Good Report is organized according to the four pillars of the Do More Good Plan, which reflect the areas where the Company can have the greatest positive impact in addressing the world’s most pressing sustainable development challenges: Sustainable Solutions; Climate & Planetary Health; Equity & Wellbeing; and Transparency & Accountability.
2022 performance highlights and achievements by IFF include:
- Recognized externally for ESG leadership, including being named to the Dow Jones Sustainability Indices for the third consecutive time, and maintaining the 2022 EcoVadis platinum sustainability rating, placing IFF among the top 1% of companies assessed;
- Enabled customers and consumers to save more CO2e than generated at IFF’s own manufacturing sites by accelerating the wider adoption of sustainable solutions in the marketplace, as documented by life cycle assessments;
- Named to the CDP Climate A list for the eighth consecutive year and completed its first virtual power purchase agreement, expected to cover approximately 30% of the total electricity needs of its European sites when it becomes operational at full capacity in 2024;
- Recertified as EDGE Move level globally for its commitment to gender parity, and included in the Bloomberg Gender-Equality Index for the second time;
- Introduced a Global Parental Leave Policy that grants a minimum of 16 weeks of 100% paid leave for a new IFF parent, regardless of gender identity or expression;
- Linked ESG performance metrics for reduction of greenhouse emissions and increases in company-wide gender representation to the Annual Incentive Plan Award for executive leaders, impacting 2022 variable compensation by 5%;
- Completed updates to its Code of Conduct training and certification campaign, achieving a 99.8% acknowledgment rate among employees.
To learn more, visit iff.com/responsibilities and use #DoMoreGoodxIFF to follow the conversation on its social channels.
Webcast
IFF will hold a live webcast to discuss the Company’s Do More Good Plan, 2022 key performance metrics, progress against 2030 goals and 2023 outlook on May 23, 2023 at 9:00 a.m. ET., where Mr. Clyburn will be joined by Michael DeVeau, Senior Vice President, Corporate Finance and Investor Relations; Dr. Greg Yep, Chief Research & Development, Global Integrated Solutions and Sustainability Officer; Ralf Finzel, Chief Operations Officer; Deborah Borg, Chief Human Resources, Diversity, Equity & Inclusion and Communications Officer; and Jennifer Johnson, General Counsel and Corporate Secretary. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com.
IFF invites investors, analysts and all IFF stakeholders to participate by phone by calling 1-404-975-4839 from the United States and toll-free from other locations by calling +1-833-470-1428. The access code for the conference call is 758853, and a listen-only webcast will be available at ir.iff.com. For those unable to listen to the live webcast, IFF will post a recorded version on the Company’s website approximately one hour after the event.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
